Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

5.33 

-0.08 -1.5%

as of Sep 29 '22

52 Week Range:

5.03 6.20


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 2.87
6.04
6.09
6.87
7.14
7.06
6.78
7.41
growth rate 110.5% 0.8% 12.8% 3.9% -1.1% -4.0% 9.3%
Earnings BIT -5.03
-11.31
-7.84
-8.91
-5.78
-4.64
-26.31
-12.40
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE 3.21
4.45
67.73
60.80
47.40
51.66
51.66
51.66
growth rate 38.6% 1,422.0% -10.2% -22.0% 9.0% 0.0% 0.0%
ROA 51.73
6.02
2.26
1.73
2.34
1.23
3.59
1.54
growth rate -88.4% -62.5% -23.5% 35.3% -47.4% 191.9% -57.1%
ROE 52.55
6.10
2.29
1.75
2.38
1.58
4.96
1.81
growth rate -88.4% -62.5% -23.6% 36.0% -33.6% 213.9% -63.5%
ROIC 50.99
3.03
-0.09
-0.42
0.69
-0.34
3.44
1.41
growth rate -94.1% -100.0% 0.0% 100.0% -100.0% 100.0% -59.0%
Cur. Ratio 56.23
74.11
81.96
56.04
41.75
1.77
4.84
2.90
growth rate 31.8% 10.6% -31.6% -25.5% -95.8% 173.5% -40.1%
Quick Ratio 56.14
73.83
81.81
55.87
41.63
1.55
4.33
2.19
growth rate 31.5% 10.8% -31.7% -25.5% -96.3% 179.4% -49.4%
Leverage 1.02
1.01
1.01
1.01
1.02
1.61
1.17
1.17
growth rate -1.0% 0.0% 0.0% 1.0% 57.8% -27.3% 0.0%
Balance Sheet Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 2.85
16.01
32.17
47.94
20.10
125.17
87.15
69.96
growth rate 461.1% 100.9% 49.1% -58.1% 522.6% -30.4% -19.7%
Acct.Payable 0.59
0.04
0.75
0.54
0.75
72.83
44.51
65.31
growth rate -93.4% 1,818.0% -27.7% 39.0% 9,585.0% -38.9% 46.7%
Cur.Assets 428.57
499.48
799.75
799.07
717.53
621.52
552.10
304.97
growth rate 16.5% 60.1% -0.1% -10.2% -13.4% -11.2% -44.8%
Total Assets 486.61
648.99
990.77
1,005.98
1,051.83
1,305.30
1,039.68
991.89
growth rate 33.4% 52.7% 1.5% 4.6% 24.1% -20.4% -4.6%
Cash 283.45
237.48
514.94
496.46
244.79
169.27
229.59
85.96
growth rate -16.2% 116.8% -3.6% -50.7% -30.9% 35.6% -62.6%
Inventory 0.60
1.46
0.79
1.22
1.14
70.87
56.51
72.40
growth rate 142.5% -45.9% 54.9% -7.2% 6,138.6% -20.3% 28.1%
Cur.Liabilities 7.62
6.74
9.76
14.26
17.19
350.80
114.06
105.30
growth rate -11.6% 44.8% 46.1% 20.5% 1,941.3% -67.5% -7.7%
Liabilities 7.62
6.93
11.05
14.78
21.80
390.20
153.44
149.87
growth rate -9.1% 59.6% 33.7% 47.6% 1,689.9% -60.7% -2.3%
LT Debt 5.02
9.27
growth rate 35.8%
Equity 478.99
642.06
979.72
991.21
1,030.03
810.73
886.24
842.02
growth rate 34.0% 52.6% 1.2% 3.9% -21.3% 9.3% -5.0%
Common Shares 57.00
97.00
121.00
143.00
761.84
723.83
694.35
628.85
growth rate 70.2% 24.7% 18.2% 432.8% -5.0% -4.1% -9.4%
Cash Flow Statement Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 0.07
0.01
0.01
0.13
0.20
0.11
5.38
3.83
growth rate -90.0% 0.0% 1,700.0% 60.3% -46.0% 4,833.9% -28.8%
Cash From OA 0.80
9.65
14.74
23.46
-5.74
4.60
-12.21
44.62
growth rate 1,101.9% 52.7% 59.2% -100.0% 100.0% -100.0% 100.0%
FCF per Share 0.01
-0.03
0.15
0.10
-0.05
-0.02
-0.20
-1.42
growth rate -100.0% 100.0% -33.3% -100.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 328.32
14.07
313.68
0.75
growth rate -95.7% 2,129.6% -99.8%
FCF 1.00
6.00
5.00
23.00
-10.00
2.00
-33.00
-180.00
growth rate 500.0% -16.7% 360.0% -100.0% 100.0% -100.0% 0.0%
Income Statement Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 0.37
1.04
5.94
8.63
12.50
47.46
199.52
243.48
growth rate 184.1% 472.8% 45.4% 44.8% 279.7% 320.4% 22.0%
Op.Income -5.03
-11.31
-7.84
-8.91
-5.78
-4.64
-26.31
-12.40
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT 131.05
37.02
23.47
21.20
29.46
22.78
32.09
6.69
growth rate -71.8% -36.6% -9.7% 39.0% -22.7% 40.8% -79.2%
Net Income 125.86
34.17
18.56
17.24
24.08
14.52
42.07
15.68
growth rate -72.9% -45.7% -7.1% 39.6% -39.7% 189.8% -62.7%
EPS 2.20
0.35
0.15
0.12
0.17
0.10
0.32
0.13
growth rate -84.1% -57.1% -20.0% 41.7% -41.2% 220.0% -59.4%
Gross Profit 0.37
0.61
4.39
7.05
10.28
26.92
81.69
115.41
growth rate 66.9% 620.9% 60.6% 45.8% 161.9% 203.5% 41.3%
R&D 1.03
2.71
1.96
2.75
1.99
3.91
11.73
12.69
growth rate 163.1% -27.8% 40.7% -27.6% 96.5% 199.6% 8.3%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT -2.24
0.02
4.02
-14.20
-0.32
growth rate 100.0% 25,031.3% -100.0% 0.0%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 81.74
90.87
105.52
69.96
83.86
growth rate 11.2% 16.1% -33.7% 19.9%
Acct.Payable 45.39
66.13
76.79
65.31
77.94
growth rate 45.7% 16.1% -15.0% 19.4%
Cur.Assets 552.52
330.03
343.07
304.97
331.01
growth rate -40.3% 4.0% -11.1% 8.5%
Total Assets 1,000.80
1,043.65
1,037.61
991.89
995.42
growth rate 4.3% -0.6% -4.4% 0.4%
Cash 271.22
102.58
92.49
85.96
113.46
growth rate -62.2% -9.8% -7.1% 32.0%
Inventory 55.04
55.78
74.91
72.40
76.65
growth rate 1.3% 34.3% -3.4% 5.9%
Cur.Liabilities 135.95
117.77
132.55
105.30
121.32
growth rate -13.4% 12.6% -20.6% 15.2%
Liabilities 171.32
154.21
165.02
149.87
165.84
growth rate -10.0% 7.0% -9.2% 10.7%
LT Debt 9.27
9.89
growth rate 6.7%
Equity 829.48
889.44
872.60
842.02
829.58
growth rate 7.2% -1.9% -3.5% -1.5%
Common Shares 641.46
668.43
652.68
628.85
619.68
growth rate 4.2% -2.4% -3.7% -1.5%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Capital Expenditures 0.19
0.24
0.69
2.71
0.05
growth rate 21.7% 191.5% 294.5% -98.1%
Cash From OA 17.21
12.41
10.32
4.68
12.88
growth rate -27.9% -16.8% -54.7% 175.1%
Sale Purchase of Stock
growth rate
FCF 17.01
12.17
9.63
1.97
12.83
growth rate -28.5% -20.9% -79.6% 552.1%
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Sales 46.07
65.80
73.34
58.27
63.81
growth rate 42.8% 11.5% -20.5% 9.5%
Op.Income -2.24
0.02
4.02
-14.20
-0.32
growth rate 100.0% 25,031.3% -100.0% 0.0%
IBT 4.43
26.58
-9.89
-14.42
-22.31
growth rate 500.3% -100.0% 0.0% 0.0%
Net Income 3.56
29.00
-8.59
-8.30
-18.81
growth rate 715.2% -100.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 20.58
28.87
37.77
28.20
32.48
growth rate 40.3% 30.8% -25.3% 15.2%
R&D 2.82
2.59
3.79
3.50
2.98
growth rate -8.3% 46.7% -7.8% -14.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (18.01)

YOY Growth Grade:

E (25.33)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 17.21 16.71 49.91
EPS / Growth 29.7% 0.32 0.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 0.5% 0.5%
Future PE 0.08 9.13 9.13
Future EPS 0.32 0.34 0.34
Value Price
MOS %
0.01
-99.9%
0.76
-85.8%
0.76
-85.8%
MOS Price 0.00 0.38 0.38
IRT 16.65 15.98 15.98

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.